Why the 21st Century Cures Act May Be in Trouble in the Senate
October 2, 2015
The rare disease community in July celebrated the passage in the House of the 21st Century Cures Act, legislation that promises among other things to accelerate the development of drugs to treat rare diseases. But the legislation appears to be stalled in the Senate as the clock is running and concern growing that it may not be getting the attention it needs to push it across the finish line. We spoke to Max Bronstein, senior director of public and government relations for the Everylife Foundation for Rare Diseases, about the legislation, where it stands today, and what it will take to see it become law.
RARECast is a weekly series by Daniel S. Levine. Levine is an award-winning business journalist who has reported on the life sciences, economic development, and business policy issues throughout his 25-year career. He founded Levine Media Group in 2013, which produces The Bio Report and RARECast podcasts. Read his full bio here.
Sign up for updates straight to your inbox.